Abstract

Professor Athanasios Mantalaris, Imperial College London, London, United Kingdom Personalized medicine is a medical model that proposes the customization of healthcare, with decisions and practices being tailored to the individual patient by use of patient-specific information (initially genetics information) and/or the application of patient-specific cell-based therapies. The BioBlood project aims to deliver personalised healthcare through a “step change” in the clinical field of haemato-oncology. BioBlood represents an engineered bio-inspired integrated experimental/modelling platform for normal and abnormal haematopoiesis that receives disease & patient input (patient primary cells & patient/disease-specific data) and will produce cellular (red blood cell product) and drug (optimal drug treatment) therapies as its output. Herein, we will present the experimental platform, which is a novel three-domensional hollow fibre bioreactor capable of culturing normal and abnormal haematopoietic cells in the absence of exogenous growth factors by mimicking the structure and function of the bone marrow, alongside a population balance model (PBM) that is able to capture cellular heterogenity and in particular leukaemia heterogenity. The PBM , which is able to extract patient- and disease-specific information is linked to a pharmacokinetic/pharmacodynamic (PD/PD) model, which is the used to optimise chemotherapy treatment in a personalised manner.